HyperHEP B® S/D [Hepatitis B Immune Globulin (Human)]
postexposure prophylaxis for hepatitis B

HyperHEP B® S/D Prescribing Information

Please refer to the HyperHEP B S/D Prescribing Information (PDF) for full prescribing details. To print a copy of the PDF, click here.

HyperHEP B S/D IMPORTANT SAFETY INFORMATION


HyperHEP B S/D should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immunoglobulin preparations. Epinephrine should be available.

In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, Hepatitis B Immune Globulin (Human) should be given only if the expected benefits outweigh the risks.

Local pain and tenderness at the injection site, urticaria, and angioedema may occur; anaphylactic reactions, although rare, have been reported following the injection of human immunoglobulin preparations.

Administration of live virus vaccines (eg, MMR) should be deferred for approximately 3 months after Hepatitis B Immune Globulin (Human) administration.

HyperHEP B S/D is made from human plasma. As with all plasma-derived therapeutics, the potential to transmit infectious agents, such as viruses and theoretically, the Creutzfeldt-Jakob (CJD) agent that can cause disease, cannot be totally eliminated. There is also the possibility that unknown infectious agents may be present in such products.

For full Prescribing Information, click here.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.